Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>M Stanley: ALI HEALTH Interim Results In Line, w/ Aim to Achieve Above-sector Growth & Further Margin Expansion
Recommend 8 Positive 11 Negative 7 |
||||
|
||||
|
Morgan Stanley's report said that ALI HEALTH (00241.HK) 1HFY25 results were in line, with revenue growing 10.2% YoY to RMB14.3 billion, slightly above its revised guidance of HSD YoY growth, on the ride of steady growth in GMV and improving take rate. Net profit for the period was RMB769 million and adjusted net profit was RMB977 million, both roughly in line. The broker cited Ali Health management's projection that with the stellar performance during the Double 11 period and potential consumption recovery, it is confident that its revenue will grow by more than 10% in FY2025, and its net profit will reach more than RMB1.5 billion, with an adjusted net profit of approximately RMB2 billion. Management further expected DD revenue growth in FY2026, and with further margin expansion, adjusted profit is expected to reach RMB2.3-2.5 billion, broadly in line with the broker's expectations. The broker's target price for Ali Health is $4.9, with an Overweight rating. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
